

# Gionata Fiorino

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/298135/gionata-fiorino-publications-by-citations.pdf>  
**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218 papers	8,979 citations	45 h-index	90 g-index
262 ext. papers	11,584 ext. citations	4.9 avg, IF	6.05 L-index

#	Paper	IF	Citations
218	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 3-25	1.5	1087
217	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1324-38	0.7	1024
216	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 144-164	1.5	427
215	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 4-22	1.5	320
214	The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , <b>2015</b> , 9, 107-24	1.5	258
213	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. <i>Journal of Crohns and Colitis</i> , <b>2015</b> , 9, 945-65	1.5	229
212	Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1385-1397.e10	6.9	219
211	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , <b>2020</b> , 69, 1213-1217	19.2	208
210	Development of the Lhann index to assess digestive tract damage in patients with Crohn's disease. <i>Gastroenterology</i> , <b>2015</b> , 148, 52-63.e3	13.3	198
209	Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 1073-80	4.5	165
208	Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. <i>Annals of Internal Medicine</i> , <b>2014</b> , 160, 704-11	8	158
207	ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 26-34	1.5	148
206	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 273-284	1.5	132
205	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 155-168	1.5	122
204	Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 1042-7	4.5	120
203	Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF- $\alpha$ agents. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 15-9	13.6	113
202	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , <b>2016</b> , 65, 1447-55	19.2	102

201	The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 233-243	4.5	96
200	Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , <b>2013</b> , 173, 250-8	6.2	94
199	Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF- $\alpha$ therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 1-10	6.1	94
198	Long-Term Safety of In Utero Exposure to Anti-TNF Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 396-403	0.7	92
197	Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 921-7	6.1	84
196	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , <b>2018</b> , 154, 1320-1333.e10	13.3	82
195	Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 1548-50	1.5	76
194	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2134-2135	6.9	71
193	The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 349-57	6.1	69
192	Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 1362-1365	1.5	67
191	Novel therapeutic targets for inflammatory bowel disease. <i>Journal of Autoimmunity</i> , <b>2017</b> , 85, 103-116	15.5	66
190	Early intervention in Crohn's disease: towards disease modification trials. <i>Gut</i> , <b>2017</b> , 66, 2179-2187	19.2	60
189	H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. <i>Gut</i> , <b>2011</b> , 60, 456-62	19.2	60
188	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 751-5	13.6	59
187	Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1065-72	4.5	56
186	Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 1330-1333	1.5	55
185	Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1179-1192	6.1	54
184	Bowel Damage as Assessed by the Lhann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 633-9	1.5	52

183	Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?. <i>Digestive Diseases</i> , <b>2012</b> , 30, 368-75	3.2	52
182	Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 1407-1419	1.5	51
181	Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2308	1.8	51
180	Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 1055-65	6.1	49
179	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. <i>Journal of Crohns and Colitis</i> , <b>2015</b> , 9, 601-6	1.5	47
178	Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis. <i>Journal of Gastrointestinal Surgery</i> , <b>2013</b> , 17, 126-32; discussion p.132	3.3	46
177	First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2013</b> , 10, 345-51	24.2	46
176	Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 595-599	5.9	46
175	Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1368-74	4.5	45
174	Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. <i>Current Drug Targets</i> , <b>2013</b> , 14, 1508-21	3	45
173	Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 762-70	0.7	43
172	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 601-606	4.5	42
171	Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 2396-400	5.6	42
170	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 2442-2451	4.5	42
169	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 1385-1391	1.5	40
168	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 1280-1287	1.5	39
167	Catching the therapeutic window of opportunity in early Crohn's disease. <i>Current Drug Targets</i> , <b>2014</b> , 15, 1056-63	3	38
166	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 963-8	3.3	36

165	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 568-579	4.5	35
164	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 338-353	3.8	34
163	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. <i>Gastroenterology</i> , <b>2017</b> , 153, 1363-1377.e6	13.3	34
162	Familial aggregation in inflammatory bowel disease: is it genes or environment?. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 2715-22	5.6	34
161	New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. <i>Current Medicinal Chemistry</i> , <b>2010</b> , 17, 1851-7	4.3	34
160	Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819848631	4.7	33
159	Perception of Reproductive Health in Women with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 886-91	1.5	32
158	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. <i>Scientific Reports</i> , <b>2019</b> , 9, 2064	4.9	32
157	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1181-1187	6.1	31
156	Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , <b>2010</b> , 6, 567-72	5.1	31
155	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 1037-1048	1.5	30
154	Positioning Therapies in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1280-1290.e1	6.1	30
153	Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1882-1883	6.9	30
152	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , <b>2018</b> , 155, 76-87	13.3	29
151	Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 274-280	1.5	29
150	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 360-70	3.3	29
149	Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 135-9	3.3	29
148	Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 4594-603	5.6	29

147	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1426-1432.e1	6.9	28
146	Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 3246-55	4	27
145	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 17-23	3.3	26
144	Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 189-201	6.1	26
143	Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 611-26	15.9	26
142	Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 239-251	3.8	24
141	Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2014</b> , 8, 835-46	4.2	24
140	MRI in Crohn's disease--current and future clinical applications. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 23-31	24.2	24
139	Risk of postoperative recurrence and postoperative management of Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 3213-9	5.6	24
138	Can IL-23 be a good target for ulcerative colitis?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 32-33, 95-102	2.5	23
137	Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. <i>Journal of Gastrointestinal Surgery</i> , <b>2014</b> , 18, 83-90; discussion 90-1	3.3	23
136	'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 127-137	1.5	23
135	The safety of biological pharmacotherapy for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 437-443	4.1	22
134	Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 872-877	3.3	22
133	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 632-639	3.3	22
132	Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2397-2415	6.9	22
131	Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner?. <i>Current Drug Targets</i> , <b>2010</b> , 11, 249-60	3	22
130	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 417-423	1.5	22



129	The biosimilar road in inflammatory bowel disease: the right way?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2014</b> , 28, 465-71	2.5	21
128	Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 30, 316-322	2.2	20
127	Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 552-5	2.4	20
126	Integrins and adhesion molecules as targets to treat inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , <b>2015</b> , 25, 67-71	5.1	20
125	Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. <i>Current Drug Targets</i> , <b>2013</b> , 14, 1444-52	3	20
124	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	19
123	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	17
122	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 941-950	6.1	17
121	Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 507-522	6.1	16
120	The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. <i>Therapeutic Advances in Gastroenterology</i> , <b>2016</b> , 9, 503-12	4.7	15
119	Preventing Collateral Damage in Crohn's Disease: The Lhann Index. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 495-500	1.5	15
118	Mucosal healing in ulcerative colitis: where do we stand?. <i>Current Drug Targets</i> , <b>2011</b> , 12, 1417-23	3	15
117	Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 405-407	8	15
116	Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2020</b> ,	1.5	15
115	JAK inhibitors: Novel developments in management of ulcerative colitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 32-33, 89-93	2.5	15
114	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IGD study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 972-977	3.3	13
113	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 507-516	24.2	13
112	Improving the quality of surveillance colonoscopy in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 971-983	18.8	13

111	Adalimumab in ulcerative colitis: hypes and hopes. <i>Expert Opinion on Biological Therapy</i> , <b>2011</b> , 11, 109-165.4	13
110	Adalimumab in Crohn's disease: tips and tricks after 5 years of clinical experience. <i>Current Medicinal Chemistry</i> , <b>2011</b> , 18, 1230-8	4.3 13
109	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 138-142	3.3 13
108	Biosimilars of adalimumab: the upcoming challenge in IBD. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 1023-1030	5.4 13
107	IL-23 Blockade for Crohn's disease: next generation of anti-cytokine therapy. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 457-467	5.1 12
106	Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. <i>Immunotherapy</i> , <b>2015</b> , 7, 175-90	3.8 12
105	Filgotinib in Crohn's Disease: JAK Is Back. <i>Gastroenterology</i> , <b>2017</b> , 153, 603-605	13.3 12
104	Biological therapy for ulcerative colitis: what is after anti-TNF. <i>Current Drug Targets</i> , <b>2011</b> , 12, 1433-9	3 12
103	State of the art: psychotherapeutic interventions targeting the psychological factors involved in IBD. <i>Current Drug Targets</i> , <b>2014</b> , 15, 1020-9	3 12
102	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1399-1407	4.5 11
101	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. <i>Digestion</i> , <b>2017</b> , 96, 166-172	3.6 11
100	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 773-99	2.8 11
99	Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 840-2	6.1 11
98	Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 499-500	6.1 11
97	New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2015</b> , 50, 113-20	2.4 10
96	Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 330-4	3.3 10
95	Are Surgical Rates Decreasing in the Biological Era In IBD?. <i>Current Drug Targets</i> , <b>2019</b> , 20, 1356-1362	3 10
94	The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 611256	8.4 10



93	Cross-sectional imaging modalities in Crohn's disease. <i>Digestive Diseases</i> , <b>2013</b> , 31, 199-201	3.2	9
92	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 480-489	1.5	9
91	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 510-515	3.3	9
90	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 1228-1235	5.3	8
89	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. <i>Cells</i> , <b>2019</b> , 8,	7.9	7
88	Impact of therapies on bowel damage in Crohn's disease. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 410-417	5.3	7
87	Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 903-905	6.1	7
86	Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. <i>Expert Review of Clinical Immunology</i> , <b>2014</b> , 10, 885-95	5.1	7
85	The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 6759-6769	3.3	7
84	Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 44-50	3.3	7
83	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 1361-1369	2.2	7
82	Hyaluronan Accelerates Intestinal Mucosal Healing through Interaction with TSG-6. <i>Cells</i> , <b>2019</b> , 8,	7.9	6
81	Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. <i>Pharmacological Research</i> , <b>2020</b> , 160, 105061	10.2	6
80	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 421-427	5.4	6
79	Vedolizumab for the treatment of Crohn's disease. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 179-189	3.9	6
78	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 7-12	3.3	6
77	Bowel damage assessment in Crohn's disease by magnetic resonance imaging. <i>Current Drug Targets</i> , <b>2012</b> , 13, 1300-7	3	6
76	New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?. <i>Current Opinion in Pharmacology</i> , <b>2020</b> , 55, 141-150	5.1	6

75	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
74	Point-of-Care Ultrasound in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, 143-151.	5	6
73	Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. <i>Clinical and Translational Science</i> , <b>2021</b> ,	4.9	6
72	Emerging therapeutic targets and strategies in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 735-44	4.2	5
71	European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 802-6	2.2	5
70	Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. <i>Cells</i> , <b>2019</b> , 8,	7.9	5
69	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX <sup>®</sup> (Cortiment <sup>®</sup> ) for active, mild-to-moderate ulcerative colitis. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 1171-1182	5.3	5
68	Commentary: anaemia in inflammatory bowel disease--the most common and ignored extra intestinal manifestation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 227-8	6.1	5
67	Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa. <i>Gastroenterology</i> , <b>2014</b> , 147, 1433-5	13.3	5
66	Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 301-6	5.1	5
65	Anti-TNF's for postoperative recurrence in Crohn's disease: the if's and how's. <i>Current Drug Targets</i> , <b>2010</b> , 11, 219-26	3	5
64	Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 280-287	4.3	5
63	Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners. <i>Journal of Crohns and Colitis</i> , <b>2020</b> ,	1.5	5
62	Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 1019-1028	5.1	5
61	439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars. <i>Gastroenterology</i> , <b>2016</b> , 150, S92	13.3	5
60	Detection and management of early stage inflammatory bowel disease: an update for clinicians. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 547-555	4.2	4
59	Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?. <i>Gastroenterology</i> , <b>2015</b> , 149, 1121-3	13.3	4
58	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 775-787	4.2	4

57	Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 927-928	6.1	4
56	Acute severe colitis: infliximab and/or cyclosporine?. <i>Current Drug Targets</i> , <b>2011</b> , 12, 1448-53	3	4
55	Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 438-442	5.3	4
54	Adalimumab for the treatment of pediatric Crohn's disease. <i>Expert Review of Clinical Immunology</i> , <b>2015</b> , 11, 963-72	5.1	3
53	The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn's disease. <i>Updates in Surgery</i> , <b>2020</b> , 72, 985-989	2.9	3
52	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 623-629	5.9	3
51	The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. <i>Current Drug Targets</i> , <b>2012</b> , 13, 1273-9	3	3
50	Golimumab: clinical update on its use for ulcerative colitis. <i>Drugs of Today</i> , <b>2015</b> , 51, 171-84	2.5	3
49	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 765-773	4.2	3
48	Medical therapy versus surgery in moderate-to-severe ulcerative colitis. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 403-408	3.3	3
47	Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. <i>Immunotherapy</i> , <b>2019</b> , 11, 565-575	3.8	2
46	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 797-806	4.2	2
45	Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 256-257	1.5	2
44	Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?. <i>Current Drug Targets</i> , <b>2018</b> , 19, 748-756	3	2
43	Mo1332 MRE and Colonoscopy Findings in Early Crohn's Disease Predict the Course of the Disease: A Prospective Observational Cohort Study. <i>Gastroenterology</i> , <b>2013</b> , 144, S-639	13.3	2
42	A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort. <i>Gastroenterology</i> , <b>2017</b> , 152, S108	13.3	2
41	Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball?. <i>Gut</i> , <b>2015</b> , 64, 1347-8	19.2	2
40	A Prospective Comparison Between 1.5T Magnetic Resonance and 3T Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience. <i>Gastroenterology</i> , <b>2011</b> , 140, S-695	13.3	2

39	Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 47-56	3.3	2
38	Personalizing Psychological Treatment Along the IBD Journey: From Diagnosis to Surgery. <i>Current Drug Targets</i> , <b>2018</b> , 19, 722-728	3	2
37	Capsule endoscopy in Crohn's disease. <i>Current Drug Targets</i> , <b>2012</b> , 13, 1261-7	3	2
36	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , <b>2021</b> ,	1.5	2
35	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, e134-e136	4.5	2
34	Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1719-1721	0.7	2
33	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	2
32	Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 712-716	3.3	2
31	Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?. <i>Current Drug Targets</i> , <b>2021</b> , 22, 347-355	3	2
30	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 4276-4297	5.6	2
29	Nursing-sensitive outcomes in adult inflammatory bowel disease: A systematic review. <i>Journal of Advanced Nursing</i> , <b>2021</b> , 77, 2248-2266	3.1	2
28	Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. <i>Gastroenterology</i> , <b>2019</b> , 156, 2349-2351	13.3	1
27	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 819-828	4.2	1
26	Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 277-8	6.1	1
25	Commentary: Adjunct antibiotic combination therapy for ulcerative colitis--is it time to investigate <i>Fusobacterium varium</i> ?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1333	6.1	1
24	Commentary: antibodies reacting with the infliximab Fab portion--something new?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 552	6.1	1
23	Anti-TNF Therapy in Inflammatory Bowel Diseases. <i>Frontiers of Gastrointestinal Research</i> , <b>2009</b> , 95-107		1
22	Postoperative recurrence of Crohn's disease and videocapsule endoscopy: it is necessary to leave no stone unturned. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 1165-6	4.5	1

21	Iron deficiency: the hidden miscreant in inflammatory bowel disease. <i>Current Drug Targets</i> , <b>2014</b> , 15, 1011-9	3	1
20	Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1432-1441	6.1	1
19	Thrombosis in IBD in the Era of JAK Inhibition. <i>Current Drug Targets</i> , <b>2021</b> , 22, 126-136	3	1
18	Protecting patients with IBD during the COVID-19 pandemic. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 639	18.8	1
17	Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. <i>Minerva Gastroenterology</i> , <b>2017</b> , 63, 319-326	3	1
16	Diagnosis and Outcome of Oesophageal Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 624-629	5	1
15	Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 829-841	4.2	1
14	Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey. <i>Gastroenterology Nursing</i> , <b>2021</b> , 44, E59-E66	1	1
13	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211005692	4.7	1
12	Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study.. <i>United European Gastroenterology Journal</i> , <b>2022</b> ,	5.3	1
11	Psychological Functioning of Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, e112	4.5	0
10	TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease. <i>Current Drug Targets</i> , <b>2021</b> , 22, 760-769	3	0
9	Inflammatory Bowel Disease in Migrant Populations: Should we Look Even Further Back?. <i>Current Drug Targets</i> , <b>2021</b> , 22, 1706-1715	3	0
8	Proactive TDM for Crohn's Disease Patients in Clinical Remission Under Anti-TNF Treatment: Current State of Evidence. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 1338-1339	1.5	
7	M1410: Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial. <i>Gastrointestinal Endoscopy</i> , <b>2010</b> , 71, AB213-AB214	5.2	
6	The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases. <i>Digestive and Liver Disease Supplements</i> , <b>2010</b> , 4, 1-3		
5	Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report. <i>Digestive and Liver Disease Supplements</i> , <b>2010</b> , 4, 25-27		
4	Role of Imaging in Detecting Bowel Fibrosis and Bowel Damage <b>2019</b> , 125-139		

3	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , <b>2021</b> , 22, 370-378	3
2	Adalimumab biosimilar in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 775-776	18.8
1	JAK inhibitors in crohn's disease: ready to go?. <i>Expert Opinion on Investigational Drugs</i> , <b>2022</b> , 1-17	5.9